bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
| Revenue (TTM) | $5.66M |
| Gross Profit (TTM) | $1.87M |
| EBITDA | $-11.10M |
| Operating Margin | -267.60% |
| Return on Equity | -623.00% |
| Return on Assets | -107.10% |
| Revenue/Share (TTM) | $2.09 |
| Book Value | $0.81 |
| Price-to-Book | 1.42 |
| Price-to-Sales (TTM) | 0.88 |
| EV/Revenue | 0.624 |
| EV/EBITDA | -0.21 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -27.10% |
| Shares Outstanding | $6.28M |
| Float | $4.42M |
| % Insiders | 2.29% |
| % Institutions | 6.44% |
Volatility is currently contracting
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technology reports continued acceleration in commercial sales for its CyPath® Lung diagnostic with more than 200% growth year-over-year.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies reports on preclinical findings that demonstrate siRNA therapy kills skin cancer cells while sparing healthy cells.
JERSEY CITY, N.J., June 18, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, closed its previously announced public offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
SAN ANTONIO, Texas--(BUSINESS WIRE)-- #BIAF--bioAffinity Technologies announces closing of $3.2 million offering.
JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.
bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies announces joint webinar with Philips and 4DMedical on diagnostic and imaging technologies to support lung health in veterans.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--The Society for Advanced Bronchoscopy to host June 16 webinar featuring CyPath Lung's role in detection and management of early-stage lung cancer.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #BIAF--bioAffinity Technologies receives notice of allowance for Mexican patent on methods of predicting the likelihood of lung cancer using flow cytometry.
SAN ANTONIO--(BUSINESS WIRE)---- $BIAF #CyPathLung--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath® Lung unit sales growth so far this year continues to exceed the Company's internal pr.
